Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Entropy (Basel) ; 25(12)2023 Nov 22.
Artigo em Inglês | MEDLINE | ID: mdl-38136452

RESUMO

The future quantum internet will leverage existing communication infrastructures, including deployed optical fibre networks, to enable novel applications that outperform current information technology. In this scenario, we perform a feasibility study of quantum communications over an industrial 224 km submarine optical fibre link deployed between Southport in the United Kingdom (UK) and Portrane in the Republic of Ireland (IE). With a characterisation of phase drift, polarisation stability and the arrival time of entangled photons, we demonstrate the suitability of the link to enable international UK-IE quantum communications for the first time.

2.
J Steroid Biochem Mol Biol ; 165(Pt A): 121-123, 2017 01.
Artigo em Inglês | MEDLINE | ID: mdl-27378492

RESUMO

Congenital adrenal hyperplasia (CAH) owing to 21-hydroxylase deficiency is an autosomal recessive disorder caused by mutations in the CYP21A2 gene. Females affected with classical CAH are at risk for genital ambiguity, but can be treated in utero with dexamethasone before 9 gestational weeks to prevent virilization. Early genetic diagnosis is unavailable through current invasive methods of chorionic villus sampling and amniocentesis. New developments in prenatal genetic testing utilize fetal DNA extracted from maternal blood through noninvasive methods, which allow the determination of fetal gender and the diagnosis of CAH at an early gestational age (<9 weeks). Noninvasive prenatal diagnosis allows for the establishment of early and effective management plans in fetuses at risk for CAH and avoids unnecessary prenatal dexamethasone treatment.


Assuntos
Hiperplasia Suprarrenal Congênita/diagnóstico , Hiperplasia Suprarrenal Congênita/genética , Diagnóstico Pré-Natal/métodos , DNA/análise , DNA/sangue , Dexametasona/uso terapêutico , Feminino , Genes Recessivos , Idade Gestacional , Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Masculino , Mutação , Gravidez , Virilismo/prevenção & controle
3.
Proc Natl Acad Sci U S A ; 113(1): 164-9, 2016 Jan 05.
Artigo em Inglês | MEDLINE | ID: mdl-26699482

RESUMO

Prior studies show that oxytocin (Oxt) and vasopressin (Avp) have opposing actions on the skeleton exerted through high-affinity G protein-coupled receptors. We explored whether Avp and Oxtr can share their receptors in the regulation of bone formation by osteoblasts. We show that the Avp receptor 1α (Avpr1α) and the Oxt receptor (Oxtr) have opposing effects on bone mass: Oxtr(-/-) mice have osteopenia, and Avpr1α(-/-) mice display a high bone mass phenotype. More notably, this high bone mass phenotype is reversed by the deletion of Oxtr in Oxtr(-/-):Avpr1α(-/-) double-mutant mice. However, although Oxtr is not indispensable for Avp action in inhibiting osteoblastogenesis and gene expression, Avp-stimulated gene expression is inhibited when the Oxtr is deleted in Avpr1α(-/-) cells. In contrast, Oxt does not interact with Avprs in vivo in a model of lactation-induced bone loss in which Oxt levels are high. Immunofluorescence microscopy of isolated nucleoplasts and Western blotting and MALDI-TOF of nuclear extracts show that Avp triggers Avpr1α localization to the nucleus. Finally, a specific Avpr2 inhibitor, tolvaptan, does not affect bone formation or bone mass, suggesting that Avpr2, which primarily functions in the kidney, does not have a significant role in bone remodeling.


Assuntos
Arginina Vasopressina/fisiologia , Densidade Óssea/fisiologia , Remodelação Óssea/fisiologia , Osteogênese/fisiologia , Ocitocina/fisiologia , Receptores de Vasopressinas/metabolismo , Sequência de Aminoácidos , Animais , Arginina Vasopressina/farmacologia , Western Blotting , Densidade Óssea/efeitos dos fármacos , Densidade Óssea/genética , Doenças Ósseas Metabólicas/genética , Remodelação Óssea/efeitos dos fármacos , Remodelação Óssea/genética , Deleção de Genes , Camundongos , Camundongos Mutantes , Dados de Sequência Molecular , Osteoblastos/metabolismo , Osteoblastos/fisiologia , Osteogênese/genética , Ocitocina/farmacologia , Receptores de Ocitocina/genética , Receptores de Ocitocina/metabolismo , Receptores de Vasopressinas/genética
4.
Proc Natl Acad Sci U S A ; 111(50): 17989-94, 2014 Dec 16.
Artigo em Inglês | MEDLINE | ID: mdl-25453081

RESUMO

Bisphosphonates are the most commonly prescribed medicines for osteoporosis and skeletal metastases. The drugs have also been shown to reduce cancer progression, but only in certain patient subgroups, suggesting that there is a molecular entity that mediates bisphosphonate action on tumor cells. Using connectivity mapping, we identified human epidermal growth factor receptors (human EGFR or HER) as a potential new molecular entity for bisphosphonate action. Protein thermal shift and cell-free kinase assays, together with computational modeling, demonstrated that N-containing bisphosphonates directly bind to the kinase domain of HER1/2 to cause a global reduction in downstream signaling. By doing so, the drugs kill lung, breast, and colon cancer cells that are driven by activating mutations or overexpression of HER1. Knocking down HER isoforms thus abrogates cell killing by bisphosphonates, establishing complete HER dependence and ruling out a significant role for other receptor tyrosine kinases or the enzyme farnesyl pyrophosphate synthase. Consistent with this finding, colon cancer cells expressing low levels of HER do not respond to bisphosphonates. The results suggest that bisphosphonates can potentially be repurposed for the prevention and therapy of HER family-driven cancers.


Assuntos
Antineoplásicos/farmacologia , Apoptose/efeitos dos fármacos , Difosfonatos/farmacologia , Receptores ErbB/antagonistas & inibidores , Modelos Moleculares , Anisotropia , Western Blotting , Linhagem Celular Tumoral , Cristalografia , Difosfonatos/metabolismo , Receptores ErbB/química , Receptores ErbB/metabolismo , Fluorescência , Humanos , Simulação de Dinâmica Molecular , Ligação Proteica , Conformação Proteica , Sais de Tetrazólio , Tiazóis
5.
Plant Dis ; 82(12): 1312-1318, 1998 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-30845462

RESUMO

Sclerotinia blight of peanut, caused by Sclerotinia minor, generally becomes severe only after vines meet in the row middles and a dense canopy develops. Dense foliage appears to support a microclimate conducive to the colonization of peanut limbs by S. minor. Removal of excess foliage before and during a Sclerotinia blight epidemic on the susceptible genotype NC 7 has been shown to reduce the rate of disease progress. Field tests in 1993 and 1994 examined control of Sclerotinia blight among four peanut genotypes (NC 7, VA 93B, NC Ac 18016, and Tam-span 90) with diverse canopy morphologies. Each cultivar had foliage pruned with a rotary mower once (1993 and 1994) or twice (1994) during the season. Applications of fluazinam (9.2 kg a.i./ha) were imposed on the genotype × pruning treatments. Soil temperatures under the canopy of each genotype and pruning treatment were measured and compared. Disease data were collected weekly by counting the number of feet of plants exhibiting lesions with visible fungus growth. Tamspan 90, a resistant Spanish peanut, had the least Sclerotinia blight incidence. Pruning measurably affected soil temperature for approximately 2 weeks following pruning. Removal of foliage reduced disease and increased disease control affected by fluazi-nam in fields with high disease pressure. In some tests, yields were increased by pruning through a reduction in disease pressure. Yields were lower when peanuts were pruned excessively, especially late in the season. Pruning of excessive vine growth can be an alternative, or complement, to fungicide treatments when done in midseason during favorable weather when moderate to high disease pressure occurs.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...